Effect of Pre-treatment With Magnesium Sulfate on the Duration of Deep Neuromuscular Blockade With Rocuronium

NCT ID: NCT02989272

Last Updated: 2016-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a prospective, comparative, randomized, double-blind clinical trial whose hypothesis is that pre-treatment with magnesium sulfate, due to its action at the neuromuscular junction,potentiate the duration of deep neuromuscular block following rocuronium curarization in patients undergoing general anesthesia. Magnesium sulphate has gained prominence as an adjuvant drug in anesthesia. Its use is associated with potentiation of neuromuscular blockade among other functions.

The deep neuromuscular block is defined as the one obtained by the absence of response to the sequence of four Stimuli and the presence of one or more simple stimuli in post-tetanic counts . There is no literature description of the role of magnesium sulphate in Duration of the deep neuromuscular block obtained after the muscle relaxation of patients with rocuronium This study is justified because extending the clinical duration of neuromuscular blockers may translate into gains for surgeries that require deep and long-lasting muscle relaxation as in laparoscopic and robotic surgeries. This block allows lower inflation pressures of the pneumoperitoneum to be obtained, as a result, there is a lower inflammatory and cardiorespiratory repercussion for the patient

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be selected from those who use the General Surgery Service of the Federal Hospital of Bonsucesso for medical indication or own will, obeying the inclusion and exclusion criteria. After signing the informed consent, they will be evaluated clinically and laboratorially, according to the routine of preoperative exams and pre-anesthetic outpatient evaluation. Patients will be allocated to one of two groups: control group (30 patients), who will receive pretreatment by venous infusion of saline solution; And magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg according to the random number sequence generated electronically through the QuickCalcs program (GraphPad Software, San Diego, CA) Because it is a double-blind study, both the researcher and the patient will not know which of the groups will be studied.

The principal investigator will be responsible for the delivery of sealed envelope containing the sequence of cases allocated in each of the groups to another anesthesiologist who will prepare the solution (saline or magnesium sulphate) and will record in a specific file in which group the volunteer was Allocated. Again the envelope will be sealed for tabulation later, without the knowledge of the researcher. The same principal investigator will be in charge of the measurement and recording of the data collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Magnesium Sulfate Neuromuscular Blockade Rocuronium Deep Neuromuscular Blockade

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

saline group

Control group (30 patients), who will receive Treatment by venous infusion of saline solution

Group Type PLACEBO_COMPARATOR

saline group

Intervention Type OTHER

saline group (30 patients) who will receive pretreatment by saline solution

Sulfate group

magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg

Group Type EXPERIMENTAL

Sulfate, Magnesium

Intervention Type DRUG

magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sulfate, Magnesium

magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg

Intervention Type DRUG

saline group

saline group (30 patients) who will receive pretreatment by saline solution

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Physical State American Society of Anesthesiologists (ASA) I, II and III; Body mass index between 18.5 and 24.9;Otorhinolaryngological surgeries

Exclusion Criteria

Refusal to participate in the study;

* Pregnancy or suspected pregnancy; Neuromuscular diseases, renal or hepatic impairment;
* Hepatic dysfunction;
* History or predictors of difficult airway; Hypermagnesemia (Mg\> 2.5 mEq / L);
* Hypomagnesemia (Mg \<1.7 mEq / L);
* Use of furosemide, aminoglycosides, aminophylline, azathioprine; Cyclophosphamide, anti-inflammatories and magnesium;
* Allergy to the drugs used in the study;
* Participants from other clinical studies.
* Emergency surgeries.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Federal de Bonsucesso

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

angelo jorge queiroz rangel micuci

Doctor Anesthesiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nubia V Figueiredo, master

Role: STUDY_DIRECTOR

Universidade Federal do Rio de Janeiro

Ismar L Cavalcanti, master

Role: STUDY_DIRECTOR

Federal Fluminense University

Angelo Jorge Q R Micuci, doctor anesthesiology

Role: PRINCIPAL_INVESTIGATOR

Hospital federal of Bonsucesso

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bonsucesso Federal Hospital

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Angelo Jorge Q R Micuci, doctor anesthesiology

Role: CONTACT

Phone: 21997828668

Email: [email protected]

Ismar L Cavalcanti, master

Role: CONTACT

Phone: 999822993

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Queiroz Rangel Micuci AJ, Vercosa N, Filho PAG, de Boer HD, Barbosa DD, Cavalcanti IL. Effect of pretreatment with magnesium sulphate on the duration of intense and deep neuromuscular blockade with rocuronium: A randomised controlled trial. Eur J Anaesthesiol. 2019 Jul;36(7):502-508. doi: 10.1097/EJA.0000000000001003.

Reference Type DERIVED
PMID: 30985540 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HFBonsucesso

Identifier Type: -

Identifier Source: org_study_id